nach oben

Arthritis Research & Therapy

Erschienen in:

01.10.2011 | Review

Lupus nephritis: current update

verfasst von: Ramesh Saxena, Tina Mahajan, Chandra Mohan

Erschienen in: Arthritis Research & Therapy | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Lupus nephritis is a major cause of morbidity and mortality in patients with systemic lupus erythematosus. The general consensus is that 60% of lupus patients will develop clinically relevant nephritis at some time in the course of their illness. Prompt recognition and treatment of renal disease is important, as early response to therapy is correlated with better outcome. The present review summarizes our current understanding of the pathogenic mechanisms underlying lupus nephritis and how the disease is currently diagnosed and treated.

Nur mit Berechtigung zugänglich

Appel GB, Radhakrishnan J, D'Agati V: Secondary glomerular disease. The Kidney. Edited by: Brenner BM. 2007, Philadelphia, PA: Saunders, 1067-1148. 8

Bertsias G, Gordon C, Boumpas DT: Clinical trials in SLE: lessons learned from the past as we proceed to the future - the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus. 2008, 17: 437-442. 10.1177/0961203308090031.PubMed

Mak A, Mok CC, Chu WP, To CH, Wong SN, Au TC: Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus. 2007, 16: 28-34. 10.1177/0961203306074469.PubMed

Seligman VA, Lum RF, Olson JL, Li H, Criswell LA: Demographic differences in the outcome of SLE nephritis: a retrospective analysis. Am J Med. 2002, 112: 726-729. 10.1016/S0002-9343(02)01118-X.PubMed

Cameron JS: Lupus nephritis. J Am Soc Nephrol. 1999, 10: 413-424.PubMed

Austin HA: Clinical evaluation and monitoring of systemic lupus erythematosis. Lupus. 1998, 7: 618-621. 10.1191/096120398678920749.PubMed

McCluskey RT: Lupus nephritis. Kidney Pathology Decennial 1966-1975. Edited by: Sommers SC. 1975, East Norwalk, CT: Appleton-Century Crofts, 435-450.

Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE: Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 1984, 25: 689-695. 10.1038/ki.1984.75.PubMed

Weening JJ, D'Agati VD, Schwartz MM: The classification of glomerulonephritis in systemic lupus erythematosis revisited. J Am Soc Nephrol. 2004, 15: 241-250. 10.1097/01.ASN.0000108969.21691.5D.PubMed

10.

Furness PN, Taub N: Interobserver reproducibility and application of the INS/RPS classification of lupus nephritis - a UK-wide study. Am J Surg Pathol. 2006, 30: 1030-1035. 10.1097/00000478-200608000-00015.PubMed

11.

Yokoyama H, Wada T, Hara A, Yamahana J, Nakaya I, Kobayashi M, Kokubo KS, Iwata Y, Yoshimoto K, Shimizu K, Sakai N, Furuichi KT: The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int. 2004, 66: 2382-2388. 10.1111/j.1523-1755.2004.66027.x.PubMed

12.

Davidson A, Aranow C: Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol. 2006, 18: 468-475.PubMed

13.

Kanta H, Mohan C: Murine lupus genes target 3 checkpoints in disease development - central tolerance in the adaptive immune system, peripheral amplification by innate immunity, and end-organ inflammation. Genes Immun. 2009, 10: 390-396. 10.1038/gene.2009.6.PubMed

14.

Hahn BH: Antibodies to DNA. N Engl J Med. 1998, 338: 1359-1368. 10.1056/NEJM199805073381906.PubMed

15.

D'Agati VD, Appel GB, Estes D, Knowles DM, Pirani CL: Monoclonal antibody identification of infiltrating mononuclear leukocytes in lupus nephritis. Kidney Int. 1986, 30: 573-581. 10.1038/ki.1986.223.PubMed

16.

Díaz Gallo C, Jevnikar AM, Brennan DC, Florquin S, Pacheco-Silva A, Kelley VR: Autoreactive kidney-infiltrating T-cell clones in murine lupus nephritis. Kidney Int. 1992, 42: 851-859. 10.1038/ki.1992.360.PubMed

17.

Mukherjee R, Zhang Z, Zhong R, Yin ZQ, Roopenian DC, Jevnikar AM: Lupus nephritis in the absence of renal major histocompatibility complex class I and class II molecules. J Am Soc Nephrol. 1996, 7: 2445-2452.PubMed

18.

Koh DR, Ho A, Rahemtulla A, Fung-Leung WP, Griesser H, Mak TW: Murine lupus in MRL/lpr mice lacking CD4 or CD8 T cells. Eur J Immunol. 1995, 25: 2558-2562. 10.1002/eji.1830250923.PubMed

19.

Jabs DA, Burek CL, Hu Q, Kuppers RC, Lee B, Prendergast RA: Anti-CD4 monoclonal antibody therapy suppresses autoimmune disease in MRL/Mp-lpr/lpr mice. Cell Immunol. 1992, 141: 496-507. 10.1016/0008-8749(92)90166-M.PubMed

20.

Jabs DA, Kuppers RC, Saboori AM, Burek CL, Enger C, Lee B, Prendergast RA: Effects of early and late treatment with anti-CD4 monoclonal antibody on autoimmune disease in MRL/MP-lpr/lpr mice. Cell Immunol. 1994, 154: 66-76. 10.1006/cimm.1994.1057.PubMed

21.

Radeke HH, Tschernig T, Karulin A, Schumm G, Emancipator SN, Resch K, Tary-Lehmann M: CD4⁺ T cells recognizing specific antigen deposited in glomeruli cause glomerulonephritis-like kidney injury. Clin Immunol. 2002, 104: 161-173. 10.1006/clim.2002.5246.PubMed

22.

Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK: Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest. 1996, 97: 2063-2073. 10.1172/JCI118643.PubMedCentralPubMed

23.

Koshy M, Berge D, Crow MK: Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest. 1996, 98: 826-837. 10.1172/JCI118855.PubMedCentralPubMed

24.

Devi BS, Van Noordin S, Krausz T, Davies KA: Peripheral blood lymphocytes in SLE - hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells. J Autoimmun. 1998, 11: 471-475. 10.1006/jaut.1998.0213.PubMed

25.

Kalled SL, Cutler AH, Datta SK, Thomas DW: Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol. 1998, 160: 2158-2165.PubMed

26.

Wang X, Huang W, Schiffer LE, Mihara M, Akkerman A, Hiromatsu K, Davidson A: Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum. 2003, 48: 495-506. 10.1002/art.10929.PubMed

27.

Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK: CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med. 1993, 178: 669-674. 10.1084/jem.178.2.669.PubMed

28.

Caux C, Massacrier C, Vanbervliet B, Dubois B, van Kooten C, Durand I, Banchereau J: Activation of human dendritic cells through CD40 crosslinking. J Exp Med. 1994, 180: 1263-1272. 10.1084/jem.180.4.1263.PubMed

29.

Yellin MJ, D'Agati V, Parkinson G, Han AS, Szema A, Baum D, Estes D, Szabolcs M, Chess L: Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum. 1997, 40: 124-134. 10.1002/art.1780400117.PubMed

30.

Kuroiwa T, Schlimgen R, Illei GG, McInnes IB, Boumpas DT: Distinct T cell/renal tubular epithelial cell interactions define differential chemokine production: implications for tubulointerstitial injury in chronic glomerulonephritides. J Immunol. 2000, 164: 3323-3329.PubMed

31.

van Kooten C, Gerritsma JS, Paape ME, van Es LA, Banchereau J, Daha MR: Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney. Kidney Int. 1997, 51: 711-721. 10.1038/ki.1997.102.PubMed

32.

Uhm WS, Na K, Song GW, Jung SS, Lee T, Park MH, Yoo DH: Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford). 2003, 42: 935-938. 10.1093/rheumatology/keg255.

33.

Calvani N, Richards HB, Tucci M, Pannarale G, Silvestris F: Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. Clin Exp Immunol. 2004, 138: 171-178. 10.1111/j.1365-2249.2004.02588.x.PubMedCentralPubMed

34.

Masutani K, Akahoshi M, Tsuruya K, Tokumoto M, Ninomiya T, Kohsaka T, Fukuda K, Kanai H, Nakashima H, Otsuka T, Hirakata H: Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum. 2001, 44: 2097-2106. 10.1002/1529-0131(200109)44:9<2097::AID-ART360>3.0.CO;2-6.PubMed

35.

Tucci M, Lombardi L, Richards HB, Dammacco F, Silvestris F: Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol. 2008, 154: 247-254. 10.1111/j.1365-2249.2008.03758.x.PubMedCentralPubMed

36.

Chan RW, Tam LS, Li EK, Lai FM, Chow KM, Lai KB, Li PK, Szeto CC: Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum. 2003, 48: 1326-1331. 10.1002/art.11062.PubMed

37.

Jacob CO, van der Meide PH, McDevitt HO: In vivo treatment of (NZB × NZW) F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med. 1987, 166: 798-803. 10.1084/jem.166.3.798.PubMed

38.

Peng SL, Moslehi J, Craft J: Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest. 1997, 99: 1936-1946. 10.1172/JCI119361.PubMedCentralPubMed

39.

Balomenos D, Rumold R, Theoilopoulos AN: Interferon-γ is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest. 1998, 101: 364-371. 10.1172/JCI750.PubMedCentralPubMed

40.

Bossù P, Neumann D, Del Giudice E, Ciaramella A, Gloaguen I, Fantuzzi G, Dinarello CA, Di Carlo E, Musiani P, Meroni PL, Caselli G, Ruggiero P, Boraschi D: IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci USA. 2003, 100: 14181-14816. 10.1073/pnas.2336094100.PubMedCentralPubMed

41.

Nakajima A, Hirose S, Yagita H, Okumura K: Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice. J Immunol. 1997, 158: 1466-1472.PubMed

42.

Rüger BM, Erb KJ, He Y, Lane JM, Davis PF, Hasan Q: Interleukin-4 transgenic mice develop glomerulosclerosis independent of immunoglobulin deposition. Eur J Immunol. 2000, 30: 2698-2703. 10.1002/1521-4141(200009)30:9<2698::AID-IMMU2698>3.0.CO;2-1.PubMed

43.

Singh RR, Saxena V, Zang S, Li L, Finkelman FD, Witte DP, Jacob CO: Differential contribution of IL-4 and STAT6 vs. STAT4 to the development of lupus nephritis. J Immunol. 2003, 170: 4818-4825.PubMedCentralPubMed

44.

Singh RR: IL-4 and many roads to lupuslike autoimmunity. Clin Immunol. 2003, 108: 73-79. 10.1016/S1521-6616(03)00145-1.PubMed

45.

Woltman AM, de Fijter JW, Zuidwijk K, Vlug AG, Bajema IM, van der Kooij SW, van Ham V, van Kooten C: Quantification of dendritic cell subsets in human renal tissue under normal and pathological conditions. Kidney Int. 2007, 71: 1001-1008. 10.1038/sj.ki.5002187.PubMed

46.

Krüger T, Benke D, Eitner F, Lang A, Wirtz M, Hamilton-Williams EE, Engel D, Giese B, Müller-Newen G, Floege J, Kurts C: Identification and functional characterization of dendritic cells in the healthy murine kidney and in experimental glomerulonephritis. J Am Soc Nephrol. 2004, 15: 613-621. 10.1097/01.ASN.0000114553.36258.91.PubMed

47.

Soos TJ, Sims TN, Barisoni L, Lin K, Littman DR, Dustin ML, Nelson PJ: CX(3) CR1(+) interstitial dendritic cells form a contiguous network throughout the entire kidney. Kidney Int. 2006, 70: 591-596.PubMed

48.

Fiore N, Castellano G, Blasi A, Capobianco C, Loverre A, Montinaro V, Netti S, Torres D, Manno C, Grandaliano G, Ranieri E, Schena FP, Gesualdo L: Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. Mol Immunol. 2008, 45: 259-265. 10.1016/j.molimm.2007.04.029.PubMed

49.

Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F: Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 2008, 58: 251-262. 10.1002/art.23186.PubMed

50.

Cederblad B, Blomberg S, Vallin H, Perers A, Alm GV, Rönnblom L: Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha-producing cells. J Autoimmun. 1998, 11: 465-470. 10.1006/jaut.1998.0215.PubMed

51.

Gill MA, Blanco P, Arce E, Pascual V, Banchereau J, Palucka AK: Blood dendritic cells and DC-poietins in systemic lupus erythematosus. Hum Immunol. 2002, 63: 1172-1180. 10.1016/S0198-8859(02)00756-5.PubMed

52.

Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL: Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001, 159: 237-243. 10.1016/S0002-9440(10)61689-6.PubMedCentralPubMed

53.

Bagavant H, Deshmukh US, Wang H, Ly T, Fu SM: Role for nephritogenic T cells in lupus glomerulonephritis: progression to renal failure is accompanied by T cell activation and expansion in regional lymph nodes. J Immunol. 2006, 177: 8258-8265.PubMed

54.

Schiffer L, Bethunaickan R, Ramanujam M, Huang W, Schiffer M, Tao H, Madaio MP, Bottinger EP, Davidson A: Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol. 2008, 180: 1938-1947.PubMedCentralPubMed

55.

Fujinaka H, Nameta M, Kovalenko P, Matsuki A, Kato N, Nishimoto G, Yoshida Y, Yaoita E, Naito M, Kihara I, Tomizawa S, Yamamoto T: Periglomerular accumulation of dendritic cells in rat crescentic glomerulonephritis. J Nephrol. 2007, 20: 357-363.PubMed

56.

Scholz J, Lukacs-Kornek V, Engel DR, Specht S, Kiss E, Eitner F, Floege J, Groene HJ, Kurts C: Renal dendritic cells stimulate IL-10 production and attenuate nephrotoxic nephritis. J Am Soc Nephrol. 2008, 19: 527-537. 10.1681/ASN.2007060684.PubMedCentralPubMed

57.

Monrad S, Kaplan MJ: Dendritic cells and the immunopathogenesis of systemic lupus erythematosus. Immunol Res. 2007, 37: 135-145. 10.1007/BF02685895.PubMed

58.

Coates PT, Colvin BL, Ranganathan A, Duncan FJ, Lan YY, Shufesky WJ, Zahorchak AF, Morelli AE, Thomson AW: CCR and CC chemokine expression in relation to Flt3 ligand-induced renal dendritic cell mobilization. Kidney Int. 2004, 66: 1907-1917. 10.1111/j.1523-1755.2004.00965.x.PubMed

59.

Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN: Chemokines enhance immunity by guiding naive CD8⁺ T cells to sites of CD4⁺ T cell-dendritic cell interaction. Nature. 2006, 440: 890-895. 10.1038/nature04651.PubMed

60.

Tucci M, Calvani N, Richards HB, Quatraro C, Silvestris F: The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis. Ann N Y Acad Sci. 2005, 1051: 421-432. 10.1196/annals.1361.084.PubMed

61.

Hooke DH, Gee DC, Atkins RC: Leukocyte analysis using monoclonal antibodies in human glomerulonephritis. Kidney Int. 1987, 31: 964-972. 10.1038/ki.1987.93.PubMed

62.

Alexopoulos E, Seron D, Hartley RB, Cameron JS: Lupus nephritis: correlation of interstitial cells with glomerular function. Kidney Int. 1990, 37: 100-109. 10.1038/ki.1990.14.PubMed

63.

Kootstra CJ, Sutmuller M, Baelde HJ, de Heer E, Bruijn JA: Association between leukocyte infiltration and development of glomerulosclerosis in experimental lupus nephritis. J Pathol. 1998, 184: 219-225. 10.1002/(SICI)1096-9896(199802)184:2<219::AID-PATH990>3.0.CO;2-9.PubMed

64.

Lan HY, Nikolic-Paterson DJ, Mu W, Atkins RC: Local macrophage proliferation in the pathogenesis of glomerular crescent formation in rat anti-glomerular basement membrane (GBM) glomerulonephritis. Clin Exp Immunol. 1997, 110: 233-240.PubMedCentralPubMed

65.

Holdsworth SR, Neale TJ, Wilson CB: Abrogation of macrophage-dependent injury in experimental glomerulonephritis in the rabbit. Use of an antimacrophage serum. J Clin Invest. 1981, 68: 686-698. 10.1172/JCI110304.PubMedCentralPubMed

66.

Duffield JS, Tipping PG, Kipari T, Cailhier JF, Clay S, Lang R, Bonventre JV, Hughes J: Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol. 2005, 167: 1207-1219. 10.1016/S0002-9440(10)61209-6.PubMedCentralPubMed

67.

Ikezumi Y, Hurst LA, Masaki T, Atkins RC, Nikolic-Paterson DJ: Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation. Kidney Int. 2003, 63: 83-95.PubMed

68.

Holdsworth SR, Neale TJ: Macrophage-induced glomerular injury. Cell transfer studies in passive autologous antiglomerular basement membrane antibody-initiated experimental glomerulonephritis. Lab Invest. 1984, 51: 172-180.PubMed

69.

Tipping PG, Timoshanko J: Contributions of intrinsic renal cells to crescentic glomerulonephritis. Nephron Exp Nephrol. 2005, 101: e173-e178. 10.1159/000088165.PubMed

70.

Timoshanko JR, Tipping PG: Resident kidney cells and their involvement in glomerulonephritis. Curr Drug Targets Inflamm Allergy. 2005, 4: 353-362. 10.2174/1568010054022132.PubMed

71.

Li S, Kurts C, Kontgen F, Holdsworth SR, Tipping PG: Major histocompatibility complex class II expression by intrinsic renal cells is required for crescentic glomerulonephritis. J Exp Med. 1998, 188: 597-602. 10.1084/jem.188.3.597.PubMedCentralPubMed

72.

Molano A, Lakhani P, Aran A, Burkly LC, Michaelson JS, Putterman C: TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis. Immunol Lett. 2009, 125: 119-128. 10.1016/j.imlet.2009.06.010.PubMed

73.

Timoshanko JR, Sedgwick JD, Holdsworth SR, Tipping PG: Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in murine crescentic glomerulonephritis. J Am Soc Nephrol. 2003, 14: 1785-1793. 10.1097/01.ASN.0000073902.38428.33.PubMed

74.

Ka SM, Cheng CW, Shui HA, Wu WM, Chang DM, Lin YC, Chen A: Mesangial cells of lupus-prone mice are sensitive to chemokine production. Arthritis Res Ther. 2007, 9: R67-10.1186/ar2226.PubMedCentralPubMed

75.

Reilly CM, Oates JC, Cook JA, Morrow JD, Halushka PV, Gilkeson GS: Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. J Immunol. 2000, 164: 1498-1504.PubMed

76.

Reilly CM, Oates JC, Sudian J, Crosby MB, Halushka PV, Gilkeson GS: Prostaglandin J(2) inhibition of mesangial cell iNOS expression. Clin Immunol. 2001, 98: 337-345. 10.1006/clim.2000.4985.PubMed

77.

Crispín JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, Kyttaris VC, Juang YT, Tsokos GC: Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol. 2008, 181: 8761-8766.PubMedCentralPubMed

78.

Kang HK, Liu M, Datta SK: Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol. 2007, 178: 7849-7858.PubMed

79.

Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003, 197: 711-723. 10.1084/jem.20021553.PubMedCentralPubMed

80.

Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA. 2003, 100: 2610-2615. 10.1073/pnas.0337679100.PubMedCentralPubMed

81.

Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, Ly N, Woodward RN, Fry KE, Lau AY, Prentice JG, Wohlgemuth JG, Crow MK: Coordinate overexpression of interferon-alpha induced genes in systemic lupus erythematosus. Arthritis Rheum. 2004, 50: 3958-3967. 10.1002/art.20798.PubMed

82.

Fairhurst AM, Xie C, Fu YY, Wang A, Boudreaux CD, Zhou XJ, Cibotti R, Coyle A, Connolly JE, Wakeland EK, Mohan C: Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J Immunol. 2009, 183: 6831-6838. 10.4049/jimmunol.0900742.PubMedCentralPubMed

83.

Border WA, Ruoslahti E: Transforming growth factor beta in disease: the dark side of tissue repair. J Clin Invest. 1992, 90: 1-7. 10.1172/JCI115821.PubMedCentralPubMed

84.

Nakamura T, Ebihara I, Shirato I, Tomino Y, Koide H: Increased steady-state levels of mRNA coding for extracellular matrix components in kidneys of NZB/W F1 mice. Am J Pathol. 1991, 139: 437-450.PubMedCentralPubMed

85.

Nakamura T, Ebihara I, Nagaoka I, Osada S, Tomino Y, Koide H: Effect of methylprednisolone on transforming growth factor-beta, insulin-like growth factor-I, and basic fibroblast growth factor gene expression in the kidneys of NZB/W F1 mice. Ren Physiol Biochem. 1993, 16: 105-116.PubMed

86.

Taniguchi Y, Yorioka N, Masaki T, Yamashita K, Ito T, Ueda H, Yamakido M: Role of transforming growth factor-beta 1 in glomerulonephritis. J Int Med Res. 1997, 25: 71-80.PubMed

87.

Saxena V, Lienesch DW, Zhou M, Bommireddy R, Azhar M, Doetschman T, Singh RR: Dual roles of immunoregulatory cytokine TGF-β in the pathogenesis of autoimmunity-mediated organ damage. J Immunol. 2008, 180: 1903-1912.PubMedCentralPubMed

88.

Bloom RD, Florquin S, Singer GG, Brennan DC, Kelley VR: Colony stimulating factor-1 in the induction of lupus nephritis. Kidney Int. 1993, 143: 1000-1009.

89.

Isbel NM, Hill PA, Foti R, Mu W, Hurst LA, Stambe C, Lan HY, Atkins RC, Nikolic-Paterson DJ: Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation. Kidney Int. 2001, 60: 614-625. 10.1046/j.1523-1755.2001.060002614.x.PubMed

90.

Yui MA, Brissette WH, Brennan DC, Wuthrich RP, Rubin-Kelley VE: Increased macrophage colony-stimulating factor in neonatal and adult autoimmune MRL-lpr mice. Am J Pathol. 1991, 139: 255-261.PubMedCentralPubMed

91.

Naito T, Yokoyama H, Moore KJ, Dranoff G, Mulligan RC, Kelley VR: Macrophage growth factors introduced into the kidney initiate renal injury. Mol Med. 1996, 2: 297-312.PubMedCentralPubMed

92.

Lan HY, Yang N, Nikolic-Paterson DJ, Yu XQ, Mu W, Isbel NM, Metz CN, Bucala R, Atkins RC: Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int. 2000, 57: 499-509. 10.1046/j.1523-1755.2000.00869.x.PubMed

93.

Lan HY, Mu W, Yang N, Meinhardt A, Nikolic-Paterson DJ, Ng YY, Bacher M, Atkins RC, Bucala R: De novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis. Am J Pathol. 1996, 149: 1119-1127.PubMedCentralPubMed

94.

Otukesh H, Chalian M, Hoseini R, Chalian H, Hooman N, Bedayat A, Yazdi RS, Sabaghi S, Mahdavi S: Urine macrophage migration inhibitory factor in pediatric systemic lupus erythematosus. Clin Rheumatol. 2007, 26: 2105-2107. 10.1007/s10067-007-0632-z.PubMed

95.

Hoi AY, Hickey MJ, Hall P, Yamana J, O'Sullivan KM, Santos LL, James WG, Kitching AR, Morand EF: Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol. 2006, 177: 5687-5696.PubMed

96.

Sasaki S, Nishihira J, Ishibashi T, Yamasaki Y, Obikane K, Echigoya M, Sado Y, Ninomiya Y, Kobayashi K: Transgene of MIF induces podocyte injury and progressive mesangial sclerosis in the mouse kidney. Kidney Int. 2004, 65: 469-481. 10.1111/j.1523-1755.2004.00394.x.PubMed

97.

Yang N, Nikolic-Patersonm DJ, Ng YY, Mu W, Metz C, Bacher M, Meinhardt A, Bucala R, Atkins RC, Lan HY: Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): potential role of MIF in regulating glucocorticoid production. Mol Med. 1998, 4: 413-424.PubMedCentralPubMed

98.

Lan HY, Bacher M, Yang N, Mu W, Nikolic-Paterson DJ, Metz C, Meinhardt A, Bucala R, Atkins RC: The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med. 1997, 185: 1455-1465. 10.1084/jem.185.8.1455.PubMedCentralPubMed

99.

Fu Y, Du Y, Mohan C: Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis. Clin Immunol. 2007, 124: 109-118. 10.1016/j.clim.2007.05.007.PubMed

100.

Zoja C, Liu XH, Donadelli R, Abbate M, Testa D, Corna D, Taraboletti G, Vecchi A, Dong QG, Rollins BJ, Bertani T, Remuzzi G: Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. J Am Soc Nephrol. 1997, 8: 720-729.PubMed

101.

Pérez de Lema G, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F, Schlöndorff D: Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol. 2001, 12: 1369-1382.PubMed

102.

Marks SD, Williams SJ, Tullus K, Sebire NJ: Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in pediatric lupus nephritis. Nephrol Dial Transplant. 2008, 23: 3521-3526. 10.1093/ndt/gfn270.PubMed

103.

Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Lai KB, Li PK, Szeto CC: Intrarenal cytokine gene expression in lupus nephritis. Ann Rheum Dis. 2007, 66: 886-892. 10.1136/ard.2006.063123.PubMedCentralPubMed

104.

Noris M, Bernasconi S, Casiraghi F, Sozzani S, Gotti E, Remuzzi G, Mantovani A: Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest. 1995, 73: 804-809.PubMed

105.

Wada T, Yokoyama H, Su SB, Mukaida N, Iwano M, Dohi K, Takahashi Y, Sasaki T, Furuichi K, Segawa C, Hisada Y, Ohta S, Takasawa K, Kobayashi K, Matsushima K: Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int. 1996, 49: 761-767. 10.1038/ki.1996.105.PubMed

106.

Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ: Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med. 1998, 187: 601-608. 10.1084/jem.187.4.601.PubMedCentralPubMed

107.

Hasegawa H, Kohno M, Sasaki M, Inoue A, Ito MR, Terada M, Hieshima K, Maruyama H, Miyazaki J, Yoshie O, Nose M, Fujita S: Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum. 2003, 48: 2555-2566. 10.1002/art.11231.PubMed

108.

Shimizu S, Nakashima H, Masutani K, Inoue Y, Miyake K, Akahoshi M, Tanaka Y, Egashira K, Hirakata H, Otsuka T, Harada M: Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology (Oxford). 2004, 43: 1121-1128. 10.1093/rheumatology/keh277.

109.

Shimizu S, Nakashima H, Karube K, Ohshima K, Egashira K: Monocyte chemoattractant protein-1 activates a regional Th1 immunoresponse in nephritis of MRL/lpr mice. Clin Exp Rheumatol. 2005, 23: 239-242.PubMed

110.

Anders HJ, Belemezova E, Eis V, Segerer S, Vielhauer V, Perez de Lema G, Kretzler M, Cohen CD, Frink M, Horuk R, Hudkins KL, Alpers CE, Mampaso F, Schlöndorff D: Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol. 2004, 15: 1504-1513. 10.1097/01.ASN.0000130082.67775.60.PubMed

111.

Chong BF, Mohan C: Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opin Ther Targets. 2009, 13: 1147-1153. 10.1517/14728220903196761.PubMed

112.

Wang A, Fairhurst AM, Tus K, Subramanian S, Liu Y, Lin F, Igarashi P, Zhou XJ, Batteux F, Wong D, Wakeland EK, Mohan C: CXCR4/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus. J Immunol. 2009, 182: 4448-4458. 10.4049/jimmunol.0801920.PubMedCentralPubMed

113.

Balabanian K, Couderc J, Bouchet-Delbos L, Amara A, Berrebi D, Foussat A, Baleux F, Portier A, Durand-Gasselin I, Coffman RL, Galanaud P, Peuchmaur M, Emilie D: Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. J Immunol. 2003, 170: 3392-3400.PubMed

114.

Pollak VE, Pirani CL, Schwartz FD: The natural history of the renal manifestations of systemic lupus erythematosis. J Lab Clin Med. 1964, 63: 537-550.PubMed

115.

Fiehn C, Hajjar Y, Mueller K: Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis. 2003, 62: 435-439. 10.1136/ard.62.5.435.PubMedCentralPubMed

116.

Austin HA, Boumpas DT, Vaughan EM, Balow JE: Highrisk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant. 1995, 10: 1620-1628.PubMed

117.

Lupus nephritis: prognostic factors and probability of maintaining lifesupporting renal function 10 years after the diagnosis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis. 1992, 19: 473-479.

118.

Austin HA, Kilppel JH, Balow JE: Therapy of lupus nephritis. Controlled trail of prednisone and cytotoxic drugs. N Engl J Med. 1986, 10: 614-619.

119.

Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized controlled trial. Ann Int Med. 1996, 125: 549-557.PubMed

120.

Bono L, Cameron JS, Hicks JA: The very long-term prognosis and complications of lupus nephritis and its treatment. QJM. 1999, 92: 211-218. 10.1093/qjmed/92.4.211.PubMed

121.

Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002, 46: 2121-2131. 10.1002/art.10461.PubMed

122.

Allison AC, Eugui EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000, 47: 85-118. 10.1016/S0162-3109(00)00188-0.PubMed

123.

Chan TM, Li FK, Tang CSO, Wong RWS, Fang GX, Lau CS, Wong AKM, Tong MKL, Chan KW, Lai KN: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med. 2000, 343: 1156-1162. 10.1056/NEJM200010193431604.PubMed

124.

Ginzler EM, Dooley MA, Aranow C: Mycophenolate mofetil or IV cyclophosphamide for lupus nephritis. N Engl J Med. 2005, 353: 2219-2228. 10.1056/NEJMoa043731.PubMed

125.

Appel GB, Contreras G, Dooley MA: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009, 20: 1103-1116. 10.1681/ASN.2008101028.PubMedCentralPubMed

126.

Contreras H, Sosnov J: Role of mycophenolate mofetil in the treatment of lupus nephritis. Clin J Am Soc Nephrol. 2007, 2: 879-890. 10.2215/CJN.02740707.PubMed

127.

Houssiau FA, D' Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, Garrido ER, Gilboe I-M, Tektonidou M, Blockmans D, Ravelingien I, Guern V, Depresseux G, Guillevin L, Ricard Cervera R, the MAINTAIN Nephritis Trial Group: Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010, 69: 2083-2089. 10.1136/ard.2010.131995.PubMedCentralPubMed

128.

Roman MJ, Shanker BA, Davis A: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosis. N Engl J Med. 2003, 349: 2399-2406. 10.1056/NEJMoa035471.PubMed

129.

Bruce IN, Urowitz MB, Gladman DD: Risk factors for coronary heart disease in women with systemic lupus erythematosis: the Toronto Risk Factor Study. Arthritis Rheum. 2003, 48: 3159-3167. 10.1002/art.11296.PubMed

130.

Houssiau FA, Lefevre C, Depresseaux G, Lambert M, Devogelaer JP, Nagant de Deuxchaisnes : Trabecular and cortical bone loss in systemic lupus erythematosis. Br J Rheum. 1996, 35: 244-247. 10.1093/rheumatology/35.3.244.

131.

Jones DS, Barstad PA, Field MJ, Hachmann JP, Hayag MS, Hill KW, Iverson GM, Livingston DA, Palanki MS: Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakisoligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis. J Med Chem. 1995, 38: 2138-2144. 10.1021/jm00012a013.PubMed

132.

Alarcon-Segovia D, Tumlin JA, Furie RA: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosis: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2003, 48: 442-454. 10.1002/art.10763.PubMed

133.

Sfikakis PP, Boletis JN, Lionaki S: Remission of proliferative lupus nephritis following B call depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005, 52: 501-513. 10.1002/art.20858.PubMed

134.

Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006, 8: R74-10.1186/ar1942.PubMedCentralPubMed

135.

Wallace DJ, Stohl W, Furie RA, Lisse JR, Mckay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, Mccune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW: A phase II, randomized, double-blind, placebo-controlled, doseranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009, 61: 1168-1178. 10.1002/art.24699.PubMedCentralPubMed

136.

Austin HA III, Boumpas DT, Vaughan EM: Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994, 45: 544-550. 10.1038/ki.1994.70.PubMed

137.

Barr RG, Seliger S, Appel GB: Prognosis in proliferative status and race/ethnicity. Nephrol Dial Transplant. 2003, 18: 2039-2046. 10.1093/ndt/gfg345.PubMed

138.

Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RWS, Au TK: Longterm outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med. 2006, 119: 355e25-355e33.

139.

Zandman-Goddard G, Levy Y, Shoenfeld Y: Intravenous immunoglobulin therapy and systemic lupus erythematosis. Clin Rev Allergy Immunol. 2005, 29: 219-228. 10.1385/CRIAI:29:3:219.PubMed

140.

Boletis JN, Loannidis JP, Boki KA, Moutsopoulos HM: Intravenous immunoglobulin compared with clyclophosphamide for proliferative lupus nephritis. Lancet. 1999, 354: 569-570. 10.1016/S0140-6736(99)01575-5.PubMed

141.

Tam LS, Li EK, Leung CB, Wong KC, Lai FM, Wang A, Szeto CC, Lui SF: Longterm treatment of lupus nephritis with cyclosporin A. QJM. 1998, 91: 573-580. 10.1093/qjmed/91.8.573.PubMed

142.

Dostal C, Tesar V, Rychlik I, Zabka J, Vencovsky J, Bartunkova J, Stejskalova A, Tegzova D: Effect of 1 year of cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosis: a pilot study. Lupus. 1998, 7: 29-36.PubMed

143.

Jayne D, Passweg J, Marmont A: Autologous stem cell transplantation for systemic lupus erythematosis. Lupus. 2004, 13: 168-176. 10.1191/0961203304lu525oa.PubMed

Titel: Lupus nephritis: current update
verfasst von: Ramesh Saxena
Tina Mahajan
Chandra Mohan
Publikationsdatum: 01.10.2011
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 5/2011
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar3378

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Lupus nephritis: current update

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2011

HLA-DRB1 shared epitope genotyping using the revised classification and its association with circulating autoantibodies, acute phase reactants, cytokines and clinical indices of disease activity in a cohort of South African rheumatoid arthritis patients

RETRACTED ARTICLE: Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium

Mechanisms of B cell autoimmunity in SLE

A new category of autoinflammatory disease associated with NOD2 gene mutations

Effects of short-term glucocorticoid treatment on changes in cartilage matrix degradation and chondrocyte gene expression induced by mechanical injury and inflammatory cytokines

Integrins and their ligands in rheumatoid arthritis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin